Nyxoah SA Stock News

Nyxoah SA (NASDAQ:NYXH ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Pearson Dennis - Investor Relations Olivier Taelman - Chief Executive Officer John Landry - Chief Financial Officer Conference Call Participants Jon Block - Stifel Adam Maeder - Piper Sandler Ross Osborn - Cantor Fitzgerald Suraj Kalia - Oppenheimer & Co. David Rescott - Baird Michael Polark -...

REGULATED INFORMATION Nyxoah Reports First Quarter Financial and Operating Results Company On Track for Anticipated PMA Approval in the Second Quarter of 2025 Successfully Completed FDA Validation Requirements, Final Site Inspection in Progress Mont-Saint-Guibert, Belgium – May 14, 2025, 7am CET / 1am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technol...

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), May 9, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. FMR LLC On May 2, 2025, Nyxoah receive...

REGULATED INFORMATION May 9, 2025, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 11, 2025 The board of directors of the Company is pleased to invite its securities holders to attend the annua...

INSIDE INFORMATION REGULATED INFORMATION Conditional Issuance of Shares Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), today announced a conditional issuance of up to 5 million ordinary shares under its existing at-the-market equity offering programs (the “ATM”). This brings the aggregate number of...

Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter

Nyxoah SA. / BE0974358906

Investors can contact the law firm at no cost to learn more about recovering their losses